LY3451838

DRUG2 trials

Sponsors

Eli Lilly and Company

Conditions

HealthyMigraine

Phase 1

A Study of LY3451838 in Healthy Participants

CompletedNCT03692949

Eli Lilly and CompanyHealthy

Start: 2018-12-11End: 2020-02-26Updated: 2025-09-11

Phase 2

A Study of LY3451838 in Participants With Migraine

CompletedNCT04498910

Eli Lilly and CompanyMigraine

Start: 2020-11-16End: 2022-11-09Updated: 2023-11-28

Related Papers

Preclinical and clinical evaluation of LY3451838, a PACAP-neutralizing monoclonal antibody, in randomized, double-blind, placebo-controlled phase 1 and phase 2 studies involving healthy adults and adults with treatment-resistant migraine

Cephalalgia2025-08-015 citations